USANA Health Sciences(US:USNA) ZACKS·2025-02-26 00:10Core Insights - USANA Health Sciences reported quarterly earnings of $0.64 per share, exceeding the Zacks Consensus Estimate of $0.49 per share, but down from $0.87 per share a year ago, indicating a 26.4% year-over-year decline [1] - The company achieved revenues of $213.61 million for the quarter, surpassing the Zacks Consensus Estimate by 2.43%, but down from $221.08 million year-over-year [2] - USANA Health has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates twice in the same period [2] Earnings Performance - The earnings surprise for the recent quarter was 30.61%, following a previous surprise of 14.29% when actual earnings were $0.56 against an expectation of $0.49 [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.77, with expected revenues of $238.37 million, and for the current fiscal year, the consensus EPS is $2.89 on revenues of $950.03 million [7] Stock Performance and Outlook - USANA Health shares have declined approximately 8.9% since the beginning of the year, contrasting with a 1.7% gain in the S&P 500 [3] - The company's earnings outlook is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which USANA belongs, is ranked in the top 49% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]